294,961 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Bought by Jupiter Asset Management Ltd.

Jupiter Asset Management Ltd. acquired a new position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 294,961 shares of the company's stock, valued at approximately $7,132,000. Jupiter Asset Management Ltd. owned 0.14% of Hims & Hers Health at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in HIMS. Crewe Advisors LLC acquired a new position in shares of Hims & Hers Health in the 4th quarter valued at about $28,000. Raleigh Capital Management Inc. lifted its holdings in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 1,100 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after acquiring an additional 1,413 shares during the period. US Bancorp DE grew its holdings in shares of Hims & Hers Health by 346.7% during the fourth quarter. US Bancorp DE now owns 1,943 shares of the company's stock valued at $47,000 after purchasing an additional 1,508 shares during the last quarter. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter worth approximately $48,000. Institutional investors own 63.52% of the company's stock.

Insiders Place Their Bets

In other Hims & Hers Health news, insider Michael Chi sold 7,500 shares of the firm's stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $26.00, for a total transaction of $195,000.00. Following the completion of the sale, the insider now directly owns 193,601 shares in the company, valued at approximately $5,033,626. This trade represents a 3.73 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 36,460 shares of the company's stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $27.09, for a total value of $987,701.40. Following the completion of the transaction, the chief executive officer now owns 27,918 shares in the company, valued at $756,298.62. This represents a 56.63 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 890,592 shares of company stock worth $31,677,291. Corporate insiders own 17.71% of the company's stock.

Remove Ads

Hims & Hers Health Stock Performance

HIMS traded up $1.54 during trading on Monday, reaching $34.68. The company had a trading volume of 18,074,217 shares, compared to its average volume of 22,578,645. The firm's 50-day simple moving average is $38.49 and its 200 day simple moving average is $28.23. The company has a market cap of $7.70 billion, a price-to-earnings ratio of 78.82 and a beta of 1.37. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The business had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on HIMS. TD Cowen restated a "buy" rating and set a $28.00 price objective on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Citigroup reiterated a "sell" rating and issued a $27.00 target price on shares of Hims & Hers Health in a research note on Thursday, March 6th. Needham & Company LLC increased their price objective on shares of Hims & Hers Health from $31.00 to $61.00 and gave the stock a "buy" rating in a report on Tuesday, February 25th. BTIG Research began coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a "buy" rating and a $35.00 price objective for the company. Finally, Canaccord Genuity Group lifted their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $37.23.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.